AR029451A1 - Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia - Google Patents
Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapiaInfo
- Publication number
- AR029451A1 AR029451A1 ARP000102365A ARP000102365A AR029451A1 AR 029451 A1 AR029451 A1 AR 029451A1 AR P000102365 A ARP000102365 A AR P000102365A AR P000102365 A ARP000102365 A AR P000102365A AR 029451 A1 AR029451 A1 AR 029451A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- breast cancer
- product
- composition
- human beings
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9911582.6A GB9911582D0 (en) | 1999-05-18 | 1999-05-18 | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029451A1 true AR029451A1 (es) | 2003-07-02 |
Family
ID=10853700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102365A AR029451A1 (es) | 1999-05-18 | 2000-05-17 | Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1178831A1 (fr) |
JP (1) | JP2003512301A (fr) |
AR (1) | AR029451A1 (fr) |
AU (1) | AU3820700A (fr) |
GB (1) | GB9911582D0 (fr) |
WO (1) | WO2000069467A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040024044A1 (en) * | 2000-09-08 | 2004-02-05 | Di Salle Enrico | Exemestane as chemopreventing agent |
CA2428249A1 (fr) * | 2000-11-16 | 2002-05-23 | Pharmacia & Upjohn Company | Traitement combine de maladies dependantes des oestrogenes |
EP2269603B1 (fr) * | 2001-02-19 | 2015-05-20 | Novartis AG | Traitement des tumeurs du sein avec un dérivé de la rapamycine en association avec l'exémestane |
PL392652A1 (pl) * | 2001-05-16 | 2010-12-06 | Novartis Ag | Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację |
US20090215731A1 (en) | 2005-10-19 | 2009-08-27 | Chavah Pty Ltd. | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer |
JP6091431B2 (ja) * | 2011-01-31 | 2017-03-15 | ルコラス−エム.ディー.リミテッド | 医薬的使用 |
ES2953915T3 (es) | 2014-10-22 | 2023-11-17 | Havah Therapeutics Pty Ltd | Métodos para reducir la densidad mamaria mamográfica y/o el riesgo de cáncer de mama |
CN108472302A (zh) | 2015-10-22 | 2018-08-31 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
WO2020243777A1 (fr) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation |
-
1999
- 1999-05-18 GB GBGB9911582.6A patent/GB9911582D0/en not_active Ceased
-
2000
- 2000-04-14 WO PCT/EP2000/003407 patent/WO2000069467A1/fr not_active Application Discontinuation
- 2000-04-14 JP JP2000617927A patent/JP2003512301A/ja not_active Withdrawn
- 2000-04-14 AU AU38207/00A patent/AU3820700A/en not_active Abandoned
- 2000-04-14 EP EP00917084A patent/EP1178831A1/fr not_active Withdrawn
- 2000-05-17 AR ARP000102365A patent/AR029451A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000069467A1 (fr) | 2000-11-23 |
GB9911582D0 (en) | 1999-07-21 |
AU3820700A (en) | 2000-12-05 |
EP1178831A1 (fr) | 2002-02-13 |
JP2003512301A (ja) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033555A1 (es) | Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos | |
AR028296A1 (es) | Metodos sinergisticos y composiciones para el tratamiento del cancer | |
CO4290346A1 (es) | Formas de dosificacion de liberacion controlada de azitromicina | |
ES2148838T3 (es) | Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer. | |
TR200000576T1 (tr) | Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem | |
AR019855A1 (es) | Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica | |
PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
AR028764A1 (es) | Boquilla para la aplicacion de un producto cosmetico, su procedimiento de fabricacion y dispositivo de acondicionamiento y de aplicacion que utiliza dicha boquilla | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
DK1259240T3 (da) | Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme | |
UY26456A1 (es) | Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen. | |
HRPK20041072B3 (en) | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer | |
MY138883A (en) | Use of asiatic acid for treatment of cencer | |
AR029451A1 (es) | Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia | |
AR024564A1 (es) | Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico | |
HUP0400153A2 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
ES2172171T3 (es) | Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles. | |
MXPA02010184A (es) | Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia. | |
ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
HUP0203153A2 (hu) | Kombinációs kemoterápia | |
ATE294585T1 (de) | Vorbeugung von kolorektalkrebs | |
CY1107227T1 (el) | Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ | |
AR024981A1 (es) | Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon | |
TR200002847T2 (tr) | Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |